UBS raises Moderna price target ahead of pipeline catalysts

What happened: UBS raised its price target on Moderna (MRNA) to $45 from $36, citing upcoming pipeline catalysts. The investment bank expects key clinical and regulatory updates from Moderna in the coming months. MRNA shares responded positively, climbing 7.5% on May 18 ahead of the company's participation in a conference the following week.

Market impact: The biotechnology sector, particularly companies focused on immunology and vaccines, may see increased investor interest. UBS's bullish stance on Moderna could drive further valuation repricing in the sector, with other stocks like Krystal Biotech potentially benefiting from spillover effects.

What to watch next: Investors should closely monitor Moderna's upcoming clinical data readouts, including the phase 3 data for its COVID-19 vaccine booster and the phase 2/3 data for its HIV vaccine candidate, both expected in the second half of 2022. Additionally, watch for any regulatory decisions regarding the authorization of Moderna's COVID-19 vaccine for children under 6 years old, anticipated in the coming months.